Use of virtual patient populations for rescuing discontinued drug candidates and for reducing the number of patients in clinical trials

ATLA Alternatives to Laboratory Animals

Volumn 37, Issue SUPPL. 1, 2009, Pages 39-45

  Kleiman, Marina ^a   Sagi, Yael ^a   Bloch, Naamah ^a   Agur, Zvia ^a,b  

^a Optimata Ltd   (Israel)

^b Institute for Medical Biomathematics Isarel   (Israel)

Author keywords

Discontinued compounds; In silico; Mathematical model; Oncology; Virtual clinical study

Indexed keywords

CGP 69846A; DOCETAXEL; SUNITINIB;

ACCURACY; ALGORITHM; BREAST CANCER; CLINICAL TRIAL; COMPUTER MODEL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE MODEL; DRUG EFFICACY; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; DRUG WITHDRAWAL; DYNAMICS; HEALTH CARE; HUMAN; KIDNEY CARCINOMA; MATHEMATICAL ANALYSIS; NONHUMAN; POPULATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; TREATMENT DURATION; VIRTUAL REALITY;

EID: 72249115598     PISSN: 02611929     EISSN: None     Source Type: Journal    
DOI: 10.1177/026119290903701s07     Document Type: Conference Paper

References (30)

1. Lievre, M., Menard, J., Bruckert, E., Cogneau, J., Delahaye, F., Giral, P., Leitersdorf, E., Luc, G., Masana, L., Moulin, P., Passa, P., Pouchain, D. & Siest, G. (2001). Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. British Medical Journal 322, 603-605.
2. Arakelyan, L., Merbl, Y. & Agur, Z. (2005). Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids. European Journal of Cancer 41, 159-167. (Pubitemid 40029669)
3. Arakelyan, L., Vainstein, V. & Agur, Z. (2002). A computer algorithm describing the process of vessel formation and maturation, and its use for predicting the effects of anti-angiogenic and anti-maturation therapy on vascular tumor growth. Angiogenesis 5, 203-214. (Pubitemid 36687523)
4. Gorelik, B., Ziv, I., Shohat, R., Wick, M., Hankins, W.D., Sidransky, D. & Agur, Z. (2008). Efficacy of weekly docetaxel and bevacizumab in mesenchymal chondrosarcoma: a new theranostic method combining xenografted biopsies with a mathematical model. Cancer Research 68, 9033-9040.
5. Monia, B.P., Sasmor, H., Johnston, J.F., Freier, S.M., Lesnik, E.A., Muller, M., Geiger, T., Altmann, K.H., Moser, H., & Fabbro, D. (1996). Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proceedings of the National Academy of Sciences of the USA 93, 15,481-15,484.
6. Monteith, D.K., Geary, R.S., Leeds, J.M., Johnston, J., Monia, B.P. & Levin, A.A. (1998). Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys. Toxicological Sciences 46, 365-375. (Pubitemid 29069621)
7. Bos, J.L. (1989). Ras oncogenes in human cancer: a review. Cancer Research 49, 4682-4689. (Pubitemid 19213607)
8. Cunningham, C.C., Holmlund, J.T., Schiller, J.H., Geary, R.S., Kwoh, T.J., Dorr, A. & Nemunaitis, J. (2000). A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer. Clinical Cancer Research 6, 1626-1631. (Pubitemid 30305053)
9. Rudin, C.M., Holmlund, J., Fleming, G.F., Mani, S., Stadler, W.M., Schumm, P., Monia, B.P., Johnston, J.F., Geary, R., Yu, R.Z., Kwoh, T.J., Dorr, F.A. & Ratain, M.J. (2001). Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clinical Cancer Research 7, 1214-1220.
10. Coudert, B., Anthoney, A., Fiedler, W., Droz, J.P., Dieras, V., Borner, M., Smyth, J.F., Morant, R., de Vries, M.J., Roelvink, M. & Fumoleau, P. (2001). Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report. European Journal of Cancer 37, 2194-2198.
11. Cripps, M.C., Figueredo, A.T., Oza, A.M., Taylor, M.J., Fields, A.L., Holmlund, J.T., McIntosh, L.W., Geary, R.S. & Eisenhauer, E.A. (2002). Phase II randomized study of ISIS 3521 and ISIS 5132 in patients with locally advanced or metastatic colorectal cancer: a National Cancer Institute of Canada clinical trials group study. Clinical Cancer Research 8, 2188-2192.
12. Oza, A.M., Elit, L., Swenerton, K., Faught, W., Ghatage, P., Carey, M., McIntosh, L., Dorr, A., Holmlund, J.T. & Eisenhauer, E. (2003). Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116). Gynecologic Oncology 89, 129-133.
13. Tolcher, A.W., Reyno, L., Venner, P.M., Ernst, S.D., Moore, M., Geary, R.S., Chi, K., Hall, S., Walsh, W., Dorr, A. & Eisenhauer, E. (2002). A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer, Clinical Cancer Research 8, 2530-2535.
14. Geiger, T., Muller, M., Monia, B.P. & Fabbro, D. (1997). Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clinical Cancer Research 3, 1179-1185. (Pubitemid 27319764)
15. Agur, Z., Arakelyan, L., Daugulis, P. & Ginosar, Y. (2004). Hopf point analysis for angiogenesis models. Discrete and Continuous Dynamical Systems - Series B 4, 29-38. (Pubitemid 38202953)
16. Agur, Z., Bloch, N., Gorelik, B., Kleiman, M., Kogan, Y., Sagi, Y., Sidransky, D. & Ronen, Y. (2009). Developing oncology drugs using virtual patients of vascular tumor diseases. In Systems Biology in Drug Discovery & Development (ed. D.L. Young & S. Michelson). New York, NY, USA: John Wiley & Sons. In press.
17. Feng, Y., vom Hagen, F., Pfister, F., Djokic, S., Hoffmann, S., Back, W., Wagner, P., Lin, J., Deutsch, U. & Hammes, H.P. (2007). Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression. Thrombosis & Haemostasis 97, 99-108.
18. Usuda, K., Saito, Y., Sagawa, M., Sato, M., Kanma, K., Takahashi, S., Endo, C., Chen, Y., Sakurada, A. & Fujimura, S. (1994). Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 74, 2239-2244. (Pubitemid 24322277)
19. Assikis, V.J., Do, K.A., Wen, S., Wang, X., Cho-Vega, J.H., Brisbay, S., Lopez, R., Logothetis, C.J., Troncoso, P., Papandreou, C.N. & McDonnell, T.J. (2004). Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clinical Cancer Research 10, 6770-6778. (Pubitemid 39383025)
20. Caine, G.J., Ryan, P., Lip, G.Y. and Blann, A.D. (2007). Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients. Cancer Letters 251, 296-301. (Pubitemid 46669799)
21. Maruyama, Y., Ono, M., Kawahara, A., Yokoyama, T., Basaki, Y., Kage, M., Aoyagi, S., Kinoshita, H. & Kuwano, M. (2006). Tumor growth suppression in pancreatic cancer by a putative metastasis suppressor gene Cap43/NDRG1/Drg-1 through modulation of angiogenesis. Cancer Research 66, 6233-6242.
22. Bello, C.L., Sherman, L., Zhou, J., Verkh, L., Smeraglia, J., Mount, J., & Klamerus, K.J. (2006). Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 17, 353-358.
23. Britten, C.D., Kabbinavar, F., Hecht, J.R., Bello, C.L., Li, J., Baum, C. & Slamon, D. (2008). A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemotherapy & Pharmacology 61, 515-524. (Pubitemid 350275988)
24. O'Farrell, A.M., Foran, J.M., Fiedler, W., Serve, H., Paquette, R.L., Cooper, M.A., Yuen, H.A., Louie, S.G., Kim, H., Nicholas, S., Heinrich, M.C., Berdel, W.E., Bello, C., Jacobs, M., Scigalla, P., Manning, W.C., Kelsey, S. & Cherrington, J.M. (2003). An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clinical Cancer Research 9, 5465-5476.
25. Stevenson, J.P., Yao, K.S., Gallagher, M., Friedland, D., Mitchell, E.P., Cassella, A., Monia, B., Kwoh, T.J., Yu, R., Holmlund, J., Dorr, F.A. & O'Dwyer, P.J. (1999). Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A). Journal of Clinical Oncology 17, 2227-2236.
26. Mendel, D.B., Laird, A.D., Xin, X., Louie, S.G., Christensen, J.G., Li, G., Schreck, R.E., Abrams, T.J., Ngai, T.J., Lee, L.B., Murray, L.J., Carver, J., Chan, E., Moss, K.G., Haznedar, J.O., Sukbuntherng, J., Blake, R.A., Sun, L., Tang, C., Miller, T., Shirazian, S., McMahon, G. & Cherrington, J.M. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 9, 327-337.
27. Monia, B.P., Johnston, J.F., Geiger, T., Muller, M. & Fabbro, D. (1996). Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Medicine 2, 668-675. (Pubitemid 26191954)
28. Contrera, J.F., Matthews, E.J., Kruhlak, N.L. & Benz, R.D. (2004). Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Regulatory Toxicology & Pharmacology 40, 185-206.
29. FDA (2005). Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. Available at: http://www.fda.gov/Cder/Guidance/5541fnl.pdf (Accessed 12.03.09). Rockville, MD, USA: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
30. Egawa, S., Matsumoto, K., Iwamura, M., Uchida, T., Kuwao, S. & Koshiba, K. (1997). Impact of life expectancy and tumor doubling time on the clinical significance of prostate cancer in Japan. Japanese Journal of Clinical Oncology 27, 394-400. (Pubitemid 127519261)